NAICS UNIVERSITY · Free research for insurance agents
Research and Development in Biotechnology (except Nanobiotechnology)
NAICS 541714 · United States · 2022 edition
This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
Activities described by this code
- Cloning research and experimental development laboratories
- DNA technologies (e.g., microarrays) research and experimental development laboratories
- Nucleic acid chemistry research and experimental development laboratories
- Protein engineering research and experimental development laboratories
- Recombinant DNA research and experimental development laboratories
Other activities to examine
- Conducting research and experimental development in nanotechnology (e.g., nanobiotechnology): 541713 — Research and Development in Nanotechnology
- Conducting research and experimental development in the physical, engineering, and life sciences (except nanotechnology and biotechnology): 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing: 541380 — Testing Laboratories and Services
- Providing veterinary testing services: 541940 — Veterinary Services
- Providing medical laboratory testing for humans: 621511 — Medical Laboratories
- Raising funds for health related research: 813212 — Voluntary Health Organizations
- Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use): 325414 — Biological Product (except Diagnostic) Manufacturing;
- Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use): 325411 — Medicinal and Botanical Manufacturing
Census classification reference
For educational purposes only. AI-generated insurance research and automated logic can contain errors. Independently verify classification and coverage decisions.
Compare another operationInsurance operations research — draft
Biotechnology R&D labs conduct experimental research involving microorganisms, cellular processes, recombinant DNA, protein engineering, and biomolecular technologies. Day-to-day work typically involves culturing cells or microorganisms, running assays and genetic analyses, operating specialized analytical and laboratory equipment, handling biological specimens and chemical reagents, and documenting experimental results. Labs may work under government grants, private funding, or pharma partnership agreements, and may range from small academic spinouts to mid-sized independent research organizations.
Questions to investigate
- What biosafety level(s) does the lab operate under — BSL-1, BSL-2, BSL-3 — and is any work involving CDC/USDA select agents?
- What is the approximate replacement value of specialized laboratory equipment, and are any irreplaceable biological specimens, cell lines, or cultures stored on-premises?
- Is the lab tenant-occupied or does it own the facility, and what are the lease requirements for insurance?
- Does the lab conduct any human subjects research, support clinical trials, or have any first-in-human activities in its scope?
This insurance research was generated in April 2026. It has not received a complete human review. The October 12, 2026 audit checked codes and titles only, not descriptions or coverage assertions.